Jun 01, 2019
The 2019 ASCO Annual Meeting, taking place May 31 through June 4 in Chicago, brings together more than 40,000 oncology professionals from around the world to present and discuss the latest research in cancer treatment and patient care.
New cancer research released today explores how advances in precision medicine are taking better aim at the unique drivers of individual cancers.
Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women With Advanced Breast Cancer (Abstract LBA1008)
The international, randomized phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone. Learn more.
Front-line Pembrolizumab Is Promising Alternative to Chemotherapy for Advanced Gastroesophageal Junction and Gastric Cancers (Abstract LBA4007)
The KEYNOTE-062 phase III randomized clinical trial achieved its primary endpoint, showing that for patients with PD-L1-positive, HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) cancer, initial therapy with pembrolizumab (Keytruda) resulted in comparable (non-inferior) overall survival as standard chemotherapy. Learn more.
Pembrolizumab Increases Historic Survival Rate for Certain People with Advanced Non-Small Cell Lung Cancer (Abstract LBA9015)
Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab (Keytruda) was safe and effective and substantially increased overall survival for advanced non-small cell lung cancer (aNSCLC). Learn more.
Find more information about the 2019 ASCO Annual Meeting.